STANDARD OPERATING PROCEDURE

Size: px
Start display at page:

Download "STANDARD OPERATING PROCEDURE"

Transcription

1 STANDARD OPERATING PROCEDURE Title Reference Number Archiving and the Destruction of Records SOP-RES-028 Version Number 2 Issue Date 08 th Dec 2015 Effective Date 22 nd January 2016 Review Date 22 nd January 2018 Author(s) Reviewer(s) Melanie Boulter, QA Auditor Teresa O Leary, Head of Regulatory Compliance (Interim) Authorisation (Original signatures are retained by Research & Innovation) Dr Brian Thomson Director of Research & Innovation Dr Stephen Fowlie Medical Director 24 th Nov th Dec 2015 USERS OF THIS STANDARD OPERATING PROCEDURE MUST REFER TO TO ENSURE THE MOST CURRENT VERSION IS BEING USED

2 Page 2 of Document History Version Issue Date Reason for Change Number 1 7 th May 2014 Original SOP. Replaces SOP th Dec 2015 Internal review of Archiving processes

3 Page 3 of Introduction Archiving in the context of clinical research relates to the collection of essential documents for long term storage. Essential documents are defined as those that individually and collectively permit the evaluation of the conduct of a study and the quality of the data produced according to International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) E6. Archiving also forms part of the Trusts record management process. It is a legal requirement of the Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004:1031 as amended) that all clinical trial information, including the Trial Master File (TMF), Investigator Site File (ISF) and the Pharmacy Site File (PSF) shall be recorded, handled and stored in such a way that it can be accurately reported, interpreted and verified while the confidentiality of records of trial subjects remains protected. For all types of studies, the Data Protection Act 1998 applies. 3. Purpose and Scope The purpose of this standard operating procedure (SOP) is to describe the procedure for the archiving of study documents. It defines the responsibilities of both the Investigator and Nottingham University Hospitals NHS Trust (NUH) where acting as either a Sponsor and/or hosted site. This SOP applies to all types of studies. 4. Responsibilities 4.1 NUH Sponsored studies Sponsor Where NUH is the Sponsor, responsibilities for ensuring appropriate arrangements and funding are in place for archiving study data are fulfilled by the Research and Innovation (R&I) department. This responsibility may be delegated to a third party (such as an NHS Trust hosting the research) however this must be clearly defined in an agreement and costs outlined in the initial phases. Principle Investigator (PI)/Chief Investigator (CI) The Chief Investigator signs the NUH sponsor agreement which provides details of the arranged archiving for the study data generated at NUH and the sponsor TMF. The CI/PI is also responsible for contacting R&I when the study data is ready to be archived, and if, for any reason, there is a request to retrieve the study data from archive.

4 Page 4 of 11 The CI/PI (or delegate) must complete and sign the Archiving Request form (TAFR02801) to ensure a complete chain of custody is maintained. NUH Research and Innovation (R&I) A named Archivist is appointed as the delegated individual responsible for archiving on behalf of NUH. The Archivist will facilitate the archiving and subsequent destruction of study data. Archiving duties may be delegated to appropriate individuals should the archivist deem this necessary. The Archivist will also review and maintain the Archive Log (TAFR02802) to ensure study documents are archived appropriately and retained for the minimum retention period. For multi-centre research NUH will normally delegate the responsibility of archiving study data generated at the site to the organisation hosting the study (such as an NHS Trust). This will be fully documented in an agreement. In this instance sites should follow their local archiving procedure. 4.2 NUH Hosted studies Sponsor For studies which are not sponsored by NUH, the responsibilities for defining the requirements of archiving arrangements lie with the sponsor. Archiving can still be arranged on behalf of the sponsor and the inclusion of costs for this archiving service will be outlined at the original costing of the study and fully documented in an agreement. Ultimate responsibility for the quality, integrity, confidentiality and retrieval of the documents resides with the sponsor and the investigator. NUH Research and Innovation (R&I) The NUH R&I Archivist will facilitate the archiving of study data on written request from the Sponsor. Archiving duties may be delegated to appropriate individuals should the archivist deem this necessary. Where the Sponsors archiving procedures conflict with the procedures set out in the SOP, Sponsor procedures should always take precedence, It is essential that provisions for archiving are appropriately financed by the sponsor if this responsibility is delegated to NUH in an agreement.

5 Page 5 of Definitions Archive Archivist ATIMP CI CMD CRF CRO CTIMP Documas GCP GMP HRA ICH IMP Indemnity IP ISF MA NHS NRES NUH PI PSF QC R&I R&I Approval RCM REC RPM SAE SOP SSREC TMF UKCRC A collection of historical documents or records Named individual with specific responsibilities for reviewing and maintaining the archiving procedures and archive contents Advance Therapy Investigational Medicinal Product Chief Investigator Clinical Investigation of a Medical Device Case Report Form Contract Research Organisation Clinical Trial of Investigational Medicinal Product A document management system to assist with the management, control and governance of the research and ethics processes covering research and development projects Good Clinical Practice Good Manufacturing Practice Health Research Authority International Conference on Harmonisation Investigational Medicinal Product The guarantee to be responsible for someone else s loss Intellectual Property Investigator Site File Marketing Authorisation National Health Service National Research Ethics Service Nottingham University Hospitals NHS Trust Principal Investigator Pharmacy Site File Quality Check Research and Innovation Approval issued by NUH R&I for the study to go ahead on NUH premises Research Contracts Manager Research Ethics Committee Research Project Manager Serious Adverse Event Standard Operating Procedure Site Specific Research Ethics Committees Trial Master File UK Clinical Research Collaboration

6 Page 6 of Procedure 6.1 Record retention during study conduct Filing space should be available for the storage of ISFs during the conduct of the study, normally located in an Investigator s office or local secure filing area. Access to the files should be controlled, and available only to those who require it. PSFs will usually be stored within a secure area in the clinical trials pharmacy department. The minimum requirement is for documentation to be stored in conditions that minimise the risk of damage or loss of information. The risk of damage from water should be reduced by storing documentation above floor level and away from overhead water pipes. Documentation should be located in areas with minimal variation in temperature and humidity if stored for long periods of time, and be in an area with strict fire controls. A sponsor representative may conduct monitoring visits of the study site. As part of the routine monitoring visit the monitor will assess where the ISF is located and note whether storage arrangements are satisfactory and in line with the arrangements detailed by the investigator prior to authorisation. If the interim storage of the ISF is found not to be in accordance with regulations the investigator will have to take action to ensure that the ISF is stored appropriately (this includes the PSF). 6.2 Record retention following completion of a study Retention period All essential and any other relevant documents allowing the reconstruction of a study must be archived in accordance with this SOP. Minimum retention periods are as follows: i. Until at least 5 years after the conclusion of the study; or ii. Until at least 15 years after the completion of a clinical study or until at least 2 years after the last approval of a marketing application in a region where the ICH guidelines applies (whichever occurs first); and iii. Until there are no pending or contemplating marketing applications in a region where the ICH guidelines applies or as defined in the study protocol. iv. For ATIMPs, a minimum of 30 years after the expiry date of the product, or longer if required by terms of the clinical trial authorisation.

7 Page 7 of 11 Additionally, the sponsor or other owner of the data must retain all other documentation pertaining to the study as long as the product is authorised. Appendix 1 gives guidelines outlining the duration for which the NUH R&I would expect the retention of essential documentation generated during the course of a study to be Request to Archive Data Once a study is complete, the study data must remain at site for at least 6 months following the submission of the end of study report. Prior to archiving of study data the PI/CI (or delegate) and R&I staff will be required to inspect all documentation for archiving and give special attention to any elements that may be subject to rapid deterioration or media forms that may become obsolete over the archive period. This includes but is not limited to: i. Plastic wallets liable to remove print from documents; ii. Thermochromic paper print-outs (which fade and become illegible over time); iii. Electronic media; iv. Electromagnetic tapes; v. Photographs and films; vi. Dummy IMP/medical device samples/packaging; vii. Contaminated paper documents that may cause deterioration (from fungal or insect infestation for example). The PI/CI and R&I must ensure that any documentation held electronically are printed or placed onto an appropriate electronic media storage device (and checked it will be readable for the retention period) prior to archive. This includes a copy of the study database for NUH sponsored studies, for example. The PI/CI must also liaise with any support departments involved in the study (e.g. Pharmacy, Radiology, Laboratories etc.) to ensure all documentation is collated. Archive boxes are available for collection from R&I, NHSP, C-Floor, South Block, QMC. It is the PI/CIs responsibility to obtain the appropriate number of boxes for their data and pack up their data. On request, a transfer of boxes can be made from R&I to the PI/CI, particularly if they are based at a location different to R&I. Following 6 months of the publication of the end of study report (for NUH sponsored studies) or on request of the sponsor (for non-nuh sponsored studies) the PI/CI (or delegate) must make arrangements to transfer their study data to R&I as per the address above with a completed Archive Request form (TAFR02801). Completed forms should be ed to R&IEnquiries@nuh.nhs.uk.

8 Page 8 of 11 If it is impractical for archive boxes to be transferred to R&I (i.e. due to a large volume of data) the PI/CI should request that R&I visit their location to check the study data has been packed up correctly, and make arrangements for collection for transfer to the archive facility Transfer of Study Data to Archive On receipt of the completed Archive Request form, the R&I Archivist, or delegate, will check: i. The Archive Request form has been completed correctly; ii. The box contents is as per listed on the Archive Request form; iii. The data of one study only is contained in each box (i.e. ISF data from different studies must not be archived together); iv. The volume of data to archive does not exceed the contractual obligations of NUH (if set out in the original agreement); v. The date of destruction complies with the study protocol and minimum retention period as per the regulations; vi. The archive request is valid (i.e. on agreement from the sponsor as verified by the PI/CI). R&I will direct any queries to the PI/CI to resolve. R&I may prepare the department files for the study (R&I Files or Sponsor TMF) to be archived with the study data following a final QC of the files. R&I will assign an archive barcoding label to each box for archive (labels are provided by the archive service provider. This will be logged on the Archive Log (TAFR02802). R&I will make arrangements for collection of the data by the archive service provider. Data must be transferred from R&I to archive within 30 days of a completed archive request form. The date of collection of data to archive will be documented in the Archive Log Recall of Study data from Archive Study data may be temporarily recalled from archive by the Archivist or delegate on request from the PI/CI or sponsor, often for the purposes of audit or inspection. Requests, giving the reason for recall, must be sent to R&IEnquiries@nuh.nhs.uk giving 30 days notice where possible; however recalls can be made within 3 working days if an urgent request is made.

9 Page 9 of 11 Study data recalled from archive must be handled with the same level of access control and confidentiality measures as if the study were active. All archive recalls and returns will be documented in the R&I Archive Log by the Archivist, or delegate. 6.3 Destruction of Records The Archivist, or delegate, will review the Archive Log on a regular basis to check for studies approaching or those having reached the end of the minimum retention period. The Archivist, or delegate, will endeavour to contact the sponsor to confirm the study data may be destroyed, or if further retention is required. The Destruction of Records form (TAFR02805) should be completed by the Sponsor and returned to R&Ienquiries@nuh.nhs.uk in this instance. If further retention is required NUH may request an amendment to the original agreement and revision of costs to be negotiated prior to the extension. Any extension will be documented in the Archive Log. If no response is obtained from the sponsor, or the sponsor organisation no longer exists, the Archivist, or delegate, will contact the PI/CI to confirm the study data may be destroyed (the Destruction of Records form should be completed by the CI/PI and returned to R&Ienquiries@nuh.nhs.uk in this instance). If no confirmation is received from the sponsor or the PI/CI within 30 days of initial request, the Archivist, or delegate, will proceed to request the destruction of study data. All study data will be destroyed confidentially by the archive service provider. Written confirmation of destruction will be retained in the R&I files and a copy will be provided to the sponsor and PI/CI (if contactable). Evidence of destruction must be retained for a further 5 years after the date of destruction. The Archive Log will also be updated with destruction information. 7. References and Associated Documents The Medicines for Human Use (Clinical Trials) Regulations 2004, Regulation 31A (1) of SI 2004/1031 Directive 2003/63/EC Data Protection Act 1998 TAFR02801 TAFR02803 TAFR02805 Archiving Request Form Archive Log Destruction of Records Form

10 Page 10 of 11 Appendix 2. Recommended Period of Archiving of Essential Documentation The following matrix outlines the minimum duration for which NUH R&I would retain the essential documentation generated during the course of a research study. For those studies involving investigational devices or surgical intervention, the same principles will be followed as for studies of IMPs to reflect the risk associated with these types of study. For studies that do not involve regulatory submissions i.e. non interventional research that does not involve the use of an IMP or a device, the minimum period for archiving should be at least 5 years after completion of the study in line with MHRA recommendations. # Category of Study Recommended period of retention for investigator site file Location of investigator site file Point at which files can be destroyed 1 IMP study, NUH sponsored 15 years In a suitable location on NUH premises approved by R&I or at an agreed offsite facility. 15 years after the declaration by PI of the end of the study. 2 IMP Study Non- At least 5 years Investigator should The sponsor will commercially (longer if sponsor negotiate with the sponsor notify the PI of Sponsored requires) for the off-site storage of when documents documents. If this is not can be destroyed. possible then a location on NUH approved by the R&I can be used. 3 IMP Study At least 5 years Investigator should The sponsor will Commercially (longer if sponsor negotiate with the sponsor notify the PI of Sponsored requires) for the off-site storage of when documents documents. If this is not can be destroyed. possible then a location on NUH approved by R&I can be used. 4 ATIMP study, NUH sponsored 5 ATIMP study, externally sponsored 30 years studies (#1). 30 years after the declaration by PI of the end of the 30 years studies (#2). The sponsor will notify the PI of

11 Page 11 of 11 when documents can be destroyed 6 Investigational studies (#1). 15 years after the Device Study NUH studies (#1) declaration by PI Sponsored of the end of the study. 7 Investigational Studies (#2 or Device Study Studies (#2 or #3) #3). Studies (#2 or externally #3). Sponsored 8 Surgical Intervention Studies (#1). 15 years after the Study NUH Studies (#1) declaration by PI sponsored of the end of the study. 9 Surgical Intervention Studies (#2 or Study externally Studies (#2 or #3) #3). Studies (#2 or sponsored #3). 10 Non-interventional Study 5 years In a suitable location on NUH premises approved by R&I or at an agreed offsite facility. 5 years after declaration by PI of the end of study.

IMP Management and Accountability

IMP Management and Accountability This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document

More information

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Trial Master File & Investigator Site File SOP number: TM 001 SOP category: Trial Management Version number: 03 Version

More information

GCP Basics - refresher

GCP Basics - refresher p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History

More information

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products 1 Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products SECTION TITLE DOCUMENTS 1. Contact List Including details of relevant study site staff, responsible

More information

Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic) for management, audit and inspection of clinical trials

Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic) for management, audit and inspection of clinical trials 1 2 3 4 5 6 7 1 February 2013 EMA/INS/GCP/636736/2012 Good Clinical Practice Inspectors Working Group (GCP IWG) Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic)

More information

STANDARD OPERATING PROCEDURE SOP 310

STANDARD OPERATING PROCEDURE SOP 310 STANDARD OPERATING PROCEDURE SOP 310 DEVELOPMENT OF PARTICIPANT INFORMATION SHEET AND INFORMED CONSENT FORM Version 1.3 Version date 28.03.2017 Effective date 28.03.2017 Number of pages 8 Review date April

More information

Inspections: an academic perspective

Inspections: an academic perspective Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk

More information

Study Files and Filing

Study Files and Filing Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm

More information

Sponsorship of Clinical Research Studies

Sponsorship of Clinical Research Studies Sponsorship of Clinical Research Studies Category: Summary: Equality Impact Assessment undertaken: Policy The UK Policy Framework for Health and Social Care 2017 (UKPF) and The Medicines for Human Use

More information

Author Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document

Author Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document SOP Title: Investigator s Brochure Content, Design, Amendments, Filing & Distribution Author: Clinical Research and Development Office (CRDO) Author Signature: Date: 10 October 2017 The author is signing

More information

R&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:

R&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no: Research as a Participating site STANDARD OPERATING PROCEDURE FOR OVERSIGHT SOP No: P08/PF2 V2 Effective Date: 31 st July 2013 Supersedes: P08/PF2 Revision Date: 31 st March 2014 Author: Position: Approved

More information

Trial oversight SOP for HEY-sponsored CTIMPs

Trial oversight SOP for HEY-sponsored CTIMPs R&D Department Trial oversight SOP for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored in a retrieval system

More information

Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations

Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.

More information

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical

More information

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR

More information

1 The Clinical Research Coordinator (CRC)... 1

1 The Clinical Research Coordinator (CRC)... 1 TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...

More information

MRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council

MRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council MRC Clinical Trials Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 Medical Research Council MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 MRC GUIDELINES FOR

More information

Standard Operating Procedure (SOP)

Standard Operating Procedure (SOP) Standard Operating Procedure VALIDATION AND BACKUP OF COMPUTER SYSTEMS USED IN RESEARCH SETTING AUDIENCE ISSUE Trustwide Chief Investigators and associated Research Staff setting up and managing clinical

More information

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products. 1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended

More information

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November 2010 1 Objectives Identify the importance of accuracy,

More information

Quality Site Visit Report FGK Clinical Research (FGK) GmbH, Munich Germany. Audit No. CT6018. Date of Audit: 3rd to 5th May 2017

Quality Site Visit Report FGK Clinical Research (FGK) GmbH, Munich Germany. Audit No. CT6018. Date of Audit: 3rd to 5th May 2017 Quality Site Visit Report FGK Clinical Research (FGK) GmbH, Munich Germany Head Office Address FGK Clinical Research GmbH Heimeranstrasse 35, 80339 Munich, Germany Research Centre Address FGK Clinical

More information

Quality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)

Quality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A) Quality Assurance of Investigational Medicinal Products Sue McKenzie PPQA (A) Agenda for Today IMP Regulations - CTD and Annex 13 Role of QP for IMP Challenges of IMP Manufacture for the QP IMP Regulations

More information

Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples

Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples 1 2 3 26 August 2010 EMA/INS/GCP/532137/2010 GCP Inspectors Working Group 4 5 6 Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples Draft Adoption

More information

Hospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee)

Hospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee) Page 1 of 8 Hospital Authority (HA) Guide on Research Ethics (for Study Site & Version Effective Date 2 01/02/2015 Document Number HAHO-CE&TM-HA REC Author HA Head Office Steering Committee on Research

More information

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland Question 1: What laws or regulations apply to an application for conducting a clinical

More information

Quality Assurance in Clinical Trials

Quality Assurance in Clinical Trials Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:

More information

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing

More information

ISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350. Pharmacy Manual

ISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350. Pharmacy Manual The StAmP Trial: A Proof of Principle, double blind, Randomised Placebo-Controlled, Multi Centre Trial of Statins to Ameliorate Early Onset Pre-eclampsia. ISRCTN: 23410175 EudraCT Number: 2009-012968-13

More information

Guidance for Industry - Computerized Systems Used in Clinical Trials

Guidance for Industry - Computerized Systems Used in Clinical Trials Page 1 of 14 Regulatory Information Computerized Systems Used in Clinical Trials Guidance for Industry - Computerized Systems Used in Clinical Trials

More information

Intralinks Studyspace : Electronic Investigator-Controlled Site File (eisf)

Intralinks Studyspace : Electronic Investigator-Controlled Site File (eisf) Intralinks Studyspace : Electronic Investigator-Controlled Site File (eisf) Introduction Intralinks Studyspace: Electronic Investigator-Controlled Site File (eisf) Intralinks Studyspace eisf solution is

More information

Clinical Trials application process, legislation & guidelines

Clinical Trials application process, legislation & guidelines Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission

More information

NUH PHARMACY CLINICAL TRIALS. Sheila Hodgson, Lead Pharmacist, Clinical Trials June 30th 2014

NUH PHARMACY CLINICAL TRIALS. Sheila Hodgson, Lead Pharmacist, Clinical Trials June 30th 2014 NUH PHARMACY CLINICAL TRIALS Sheila Hodgson, Lead Pharmacist, Clinical Trials June 30th 2014 Dedicated pharmacy trials staff Lead Pharmacist, Service Co-ordinator Pharmacists: Band 7 and 8a Technicians:

More information

Stephanie Gentilin, CCRA

Stephanie Gentilin, CCRA Elements of Clinical Trial Quality Assurance Stephanie Gentilin, CCRA Regulatory Coordinator SCTR SUCCESS Center QA Monitor NIDA Monitor s Responsibilities ICH E6 Section 5.18 Overall Purpose of Monitoring

More information

Commercial Archives: Advantages, Disadvantages and Risks

Commercial Archives: Advantages, Disadvantages and Risks Tim Stiles www.qualogy.co.uk Presentation title Commercial Archives: Advantages, Disadvantages and Risks 1 Scope There can be many different reasons why you may consider the need to use a contract archive.

More information

Agenzia Italiana del Farmaco

Agenzia Italiana del Farmaco Agenzia Italiana del Farmaco The Italian Legislation and the work of the Italian Medicines Agency (AIFA) in the field of ethics of Clinical Trials Umberto Filibeck AIFA Head of GCP Inspectorate and GCP

More information

OCTC 2012 CRO Selection

OCTC 2012 CRO Selection OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed

More information

Standard Operating Procedures Guidelines for Good Clinical Practice

Standard Operating Procedures Guidelines for Good Clinical Practice SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA

More information

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick

More information

OECD and EPA GLP Differences

OECD and EPA GLP Differences OECD and EPA GLP Differences Annette Leslie RQAP-GLP Du Pont Pioneer Ankeny Iowa I conduct studies in the US, so Why do I care about oecd regulations? Disclaimer: I cannot cover all the differences in

More information

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004 Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive

More information

Primary Care mcta 2013: Guidance for use

Primary Care mcta 2013: Guidance for use GUIDANCE ON USE OF THE MODEL CLINICAL TRIAL AGREEMENT FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY SPONSORED RESEARCH IN PRIMARY CARE (PRIMARY CARE mcta, 2013 VERSION) Background to the development

More information

Human Samples in Research

Human Samples in Research Human Samples in Research Import and Export of Human Tissue Document Identifier HTA-06-SOP-Import and Export AUTHOR APPROVER EFFECTIVE DATE: Name and role Signature and date Name and role Signature and

More information

The interface between Good Clinical Practice and Good Manufacturing Practice

The interface between Good Clinical Practice and Good Manufacturing Practice 1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who

More information

Essential Healthcare Research Governance Processes. Cindy Cooper, Lindsay Unwin and Judith Cohen, UoS

Essential Healthcare Research Governance Processes. Cindy Cooper, Lindsay Unwin and Judith Cohen, UoS Essential Healthcare Research Governance Processes Cindy Cooper, Lindsay Unwin and Judith Cohen, UoS Aims Overview of governance processes including recent changes to remit Reminder of HoD and PI responsibilities

More information

PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector

PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector Content Answer industry questions related to the PSMF MHRA inspector s preparation: How we

More information

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) 5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples

More information

Data Integrity in Clinical Trials the Sponsor Perspective

Data Integrity in Clinical Trials the Sponsor Perspective Data Integrity in Clinical Trials the Sponsor Perspective Maximilian Stroebe, GSK Vaccines Three differences to Commercial Manufacturing Long process chains Source Data, Clinical Sites and Outsourcing

More information

Good Clinical Practice

Good Clinical Practice Clinical Site Monitoring DMID/ICSSC 10/7/08 1 Monitoring ICH E6 5.18.1 The purpose of monitoring is to ensure that: The rights and well-being of subjects are being protected The data are accurate, complete

More information

COMPUTER SYSTEMS VALIDATION

COMPUTER SYSTEMS VALIDATION COMPUTER SYSTEMS VALIDATION DOCUMENT NO.: POL007 v1.0 AUTHOR: Lorn Mackenzie ISSUE DATE: 04 AUG 2017 1 INTRODUCTION 1.1 The Academic & Clinical Central Office for Research & Development (ACCORD) is a joint

More information

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4 EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines

More information

How to Apply for Ethics (Non-CTIMPs) including Sponsorship

How to Apply for Ethics (Non-CTIMPs) including Sponsorship How to Apply for Ethics (Non-CTIMPs) including Sponsorship Joint Research & Enterprise Office (JREO) St George s University of London Lucy H H Parker Clinical Research Governance Manager Joint Research

More information

Agenda. 16:00 16:10 Velkommen 16:10 16:15 Inspektion, hvad er det?

Agenda. 16:00 16:10 Velkommen 16:10 16:15 Inspektion, hvad er det? Agenda 16:00 16:10 Velkommen 16:10 16:15 Inspektion, hvad er det? 16:15 17:15 Electronic systems for handling of: Source data Data collection tools 17:15 17:45 Pause og networking 17:45 18:30 Trial Master

More information

Submitting a CTA application to the MHRA

Submitting a CTA application to the MHRA This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document

More information

Records management policy. Document author Assured by Review cycle. Audit and Risk Committee. 1. Introduction Purpose or aim Scope...

Records management policy. Document author Assured by Review cycle. Audit and Risk Committee. 1. Introduction Purpose or aim Scope... Records management policy Board library reference Document author Assured by Review cycle P017 Head of Compliance Audit and Risk Committee 3 Years This document is version controlled. The master copy is

More information

Audits must be conducted with due concern for employee safety and environmental protection.

Audits must be conducted with due concern for employee safety and environmental protection. Standard Operating Procedure Title: GMP Audit Procedure Related Documents TEM-080 Internal Audit Report Template TEM-120 Vendor Audit Report Template Form-385 Vendor Audit Questionnaire Form-445 EHS Workplace

More information

White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU

White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU Numerous articles are available comparing the current and previous EU Code of GMP Chapter 4: Documentation, but no comparison exists between

More information

A Guide to Efficient Trial Management. Trials Managers Network

A Guide to Efficient Trial Management. Trials Managers Network A Guide to Efficient Trial Management Trials Managers Network The Fourth Edition (2014) of the Guide to Efficient Trial Management was produced by an appointed Editorial Board and a dedicated group of

More information

HOSPITAL AUTHORITY (HA) GUIDE

HOSPITAL AUTHORITY (HA) GUIDE Page 1 of 14 HOSPITAL AUTHORITY (HA) GUIDE ON RESEARCH ETHICS (for Study Site & Research Ethics Committee) Revision Number: 1 (The document supersedes HA RE001 Hospital Authority Guide for Cluster Research

More information

SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP)

SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP) SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP) Date of Implementation: 1 August 1998 Date of First Revision: 1 October 1999 Printed in July 1998, August 1998 and September 1999. Adapted from the

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and

More information

MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155

MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part

More information

Guide to Quality System for General Sale Wholesale Distributors

Guide to Quality System for General Sale Wholesale Distributors Guide to Quality System for General Sale Wholesale Distributors IA-G0038-5 20 DECEMBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.

More information

to The Uganda Gazette No. 25, Volume CX, dated 5th May, 2017 Printed by UPPC, Entebbe, by Order of the Government No. 22.

to The Uganda Gazette No. 25, Volume CX, dated 5th May, 2017 Printed by UPPC, Entebbe, by Order of the Government No. 22. STATUTORY INSTRUMENTS SUPPLEMENT No. 13 5th May, 2017 STATUTORY INSTRUMENTS SUPPLEMENT to The Uganda Gazette No. 25, Volume CX, dated 5th May, 2017 Printed by UPPC, Entebbe, by Order of the Government.

More information

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework 1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health

More information

Standard Operating Procedures (SOPs) to achieve Good Clinical Practice (GCP) in Australian Clinical Research

Standard Operating Procedures (SOPs) to achieve Good Clinical Practice (GCP) in Australian Clinical Research Standard Operating Procedures (SOPs) to achieve Good Clinical Practice (GCP) in Australian Clinical Research September 2007 Version 1.0 Prepared by Nucleus Network on behalf of VMIA Introduction to the

More information

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time

More information

QM-1 QUALITY MANAGEMENT SYSTEMS MANUAL. Revision 10

QM-1 QUALITY MANAGEMENT SYSTEMS MANUAL. Revision 10 QM-1 QUALITY MANAGEMENT SYSTEMS MANUAL Revision 10 Page: 1 of 54 TABLE OF CONTENTS 1. DOCUMENT REVISION HISTORY... 5 2. INTRODUCTION... 6 2.1 Purpose... 6 2.2 Scope... 7 Figure 1: Sequence and Interaction

More information

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE CANCER CENTER SCIENTIFIC REVIEW COMMITTEE The Clinical Scientific Review Committee (SRC) at The Medical College of Wisconsin Cancer Center plays a vital role in protocol review and monitoring to ensure

More information

How to rescue a clinical trial

How to rescue a clinical trial How to rescue a clinical trial Clinical trial conduct is demanding and rigorous, especially in orphan indications where patient populations are small. Even well-qualified, specifically selected Contract

More information

CODE OF PRACTICE FOR RESEARCH

CODE OF PRACTICE FOR RESEARCH CODE OF PRACTICE FOR RESEARCH Dr Diana Leighton REF Manager Professor Andy Young Director of Research & Innovation Services Version 1.0 - September 2010 First approved Academic Board 27 September 2010

More information

Temporary Storage Facilities Manual

Temporary Storage Facilities Manual Temporary Storage Facilities Manual Queries: customsreliefs@revenue.ie This manual provides a guide on the authorisation and control of Temporary Storage Facilities. Published by Authorisations and Reliefs

More information

Brexit Guidance for Stakeholders Human and veterinary medicines

Brexit Guidance for Stakeholders Human and veterinary medicines Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject

More information

Good Clinical Practice

Good Clinical Practice Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie

More information

Procurement Procedure. (Standard Operating Procedure)

Procurement Procedure. (Standard Operating Procedure) Procedure (Standard Operating Procedure) Procedure Policy : Executive Summary: Policy The Procedure provides guidance on the appropriate procurement process to all Trust Staff and Budget Holders involved

More information

Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE

Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE In completing this form please refer to the attached Notes of Guidance Application for approval of all studies involving Healthy

More information

The World Bank Audit Firm Assessment Questionnaire

The World Bank Audit Firm Assessment Questionnaire The World Bank Audit Firm Assessment Questionnaire Assessment of audit firms in the Africa Region Background The Bank s financial management Bank Procedures (BP) and Operations Policy (OP) (BP/OP 10.00)

More information

BS EN ISO 9001 QUALITY ASSURANCE MANUAL

BS EN ISO 9001 QUALITY ASSURANCE MANUAL PAC PRICE ARTHUR CONSULTANCY BS EN ISO 9001 QUALITY ASSURANCE MANUAL COPY NO: 025 ISSUE: 4 QUALITY ASSURANCE MANUAL BS EN ISO 9001 CONTENTS PAC Price Arthur Consultancy - Building Services Consulting Engineers

More information

Association of American Railroads Quality Assurance System Evaluation (QASE) Checklist Rev. 1/12/2017

Association of American Railroads Quality Assurance System Evaluation (QASE) Checklist Rev. 1/12/2017 Company: Prepared By: Date: Changes from previous version highlighted in yellow. Paragraph Element Objective Evidence 2.1 Objective of Quality Assurance Program 2.2 Applicability and Scope 2.3 QA Program

More information

Human Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance

Human Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Human Research Audit Program Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Monday, September 11, 2017 Objectives 1. Understand the purpose of the audit program 2. Identify

More information

Introduction to Clinical Research

Introduction to Clinical Research Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that

More information

Quality Audit Report. Name of Auditee Auditee Address. Audit No. CT 5500

Quality Audit Report. Name of Auditee Auditee Address. Audit No. CT 5500 Quality Audit Report Name of Auditee Auditee Address Audit No. CT 5500 Date of Audit: 9 th -12 th January 2017 Head Office Address xxxxxx xxxxxx Research Centre Address xxxxxx xxxxxx Protocol Titles:Not

More information

Multi-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18

Multi-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18 Multi-Site Coordination Process Drafted by: Ester Dimayuga Page 1 of 18 MULTI-SITE COORDIATIO (MSC) REGULATOR PROCESS CTO-Regulatory notifies MSC of trial with UMCC as coordinating center MSC prepares

More information

SAI Global Full Service Team

SAI Global Full Service Team General information regarding elements of the certification process is described below. A degree of flexibility and options in the certification process are available so please feel free to contact us

More information

Clinical Research & ICH GCP E6(R2) (Basic / Refresher Training):

Clinical Research & ICH GCP E6(R2) (Basic / Refresher Training): Clinical Research & ICH GCP E6(R2) (Basic / Refresher Training): Principles of GCP, Investigator Responsibilities, Essential Documents v3 01-Feb-2017 Objectives To provide refresher training on ICH GCP

More information

Comparison of admission rates to neonatal units between PO screening and non-po screening Units

Comparison of admission rates to neonatal units between PO screening and non-po screening Units London - Westminster Research Ethics Committee 4 Minshull Street Manchester M1 3DZ Telephone: 0207 104 8012 Please note: This is the favourable opinion of the REC only and does not allow you to start your

More information

8 th February 2011 Responsibility for implementation

8 th February 2011 Responsibility for implementation National Ambulance Service (NAS) Ambulance Operations (Fleet) Procedure Vehicle Daily Inspection and Inventory Check Document reference number NASOF002 Revision number 9 Document developed by Document

More information

Quality Assurance in Clinical Trials Introduction

Quality Assurance in Clinical Trials Introduction Quality Assurance in Clinical Trials Introduction Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 2012 1 Delphine TEPPE-CROITROU - Catherine CORNU (Hospices Civils de Lyon)

More information

Revision. Quality Manual. Multilayer Prototypes. Compliant to ISO / AS9100 Rev C

Revision. Quality Manual. Multilayer Prototypes. Compliant to ISO / AS9100 Rev C 1 of 29 Quality Manual Multilayer Prototypes Compliant to ISO 9001-2008 / AS9100 Rev C This Quality Manual sets forth the quality system policies and Defines compliance with the ISO 9001-2008 SAE AS 9100

More information

Preparing for Close-Out of Studies and Sites

Preparing for Close-Out of Studies and Sites Preparing for Close-Out of Studies and Sites Presented by: Christie Thomas, MPH, CCRA Matthew Wright, BS, CCRP Dikla Blumberg, PhD CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced

More information

Guide for Distributors of Medical Devices

Guide for Distributors of Medical Devices Guide for Distributors of Medical Devices IA-G0004-1 8 FEBRUARY 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 SCOPE 3

More information

FEC QUALITY MANUAL. Federal Equipment Company River Rd. Cincinnati, Ohio

FEC QUALITY MANUAL. Federal Equipment Company River Rd. Cincinnati, Ohio QMS-20 2016 FEC QUALITY MANUAL Federal Equipment Company 5298 River Rd Cincinnati, Ohio 45233 www.federalequipment.com www.fecheliports.com www.usdrillhead.com www.orionseals.com www.tkf.com REVISION:

More information

APPLICANT'S CHECKLIST

APPLICANT'S CHECKLIST APPLICANT'S CHECKLIST Research tissue bank (or other research biobank) REC Ref: Title of Tissue Bank: Applicant's Name: Name of Designated Individual: Please complete this checklist and send it with your

More information

Source Documents and Regulatory Binders October 6, 2016

Source Documents and Regulatory Binders October 6, 2016 Source Documents and Regulatory Binders October 6, 2016 Lisa Wilson, Regulatory Lead, Clinical Trials Office and Mark Alger, CRC, Clinical Trials Office Essential Documents AKA: the stuff in the Reg Binder

More information

Burton Hospitals NHS Foundation Trust. On: 22 January Review Date: December Corporate / Directorate. Department Responsible for Review:

Burton Hospitals NHS Foundation Trust. On: 22 January Review Date: December Corporate / Directorate. Department Responsible for Review: POLICY DOCUMENT Burton Hospitals NHS Foundation Trust DATA QUALITY POLICY Approved by: Trust Management Team On: 22 January 2016 Review Date: December 2018 Corporate / Directorate Clinical / Non Clinical

More information

Quality Assurance Policy and Procedures

Quality Assurance Policy and Procedures 650 Montana Ave, Suite A Las Cruces, NM 88001 (575) 522-0430 www.rmgovernmentservices.com Quality Assurance Policy and Procedures PURPOSE. The purpose of this policy is to outline the quality assurance

More information

1. Number. Except as otherwise permitted by the applicable NASDAQ rules, the Audit Committee shall consist of at least three members of the Board.

1. Number. Except as otherwise permitted by the applicable NASDAQ rules, the Audit Committee shall consist of at least three members of the Board. SELECTA BIOSCIENCES, INC. AUDIT COMMITTEE CHARTER A. PURPOSE The purpose of the Audit Committee of the Board of Directors (the Board ) of Selecta Biosciences, Inc. (the Company ) is to assist the Board

More information

Standard Operating Procedures (SOPs)

Standard Operating Procedures (SOPs) Organizational Strategies for Clinical Trials Standard Operating Procedures (SOPs) SUSAN JACKSON, MPA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE UNC CENTER

More information

GxP Auditing, Remediation, and Quality System Resourcing

GxP Auditing, Remediation, and Quality System Resourcing GxP Auditing, Remediation, and Quality System Resourcing TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing

More information

GOOD CLINICAL PRACTICE (GCP) Series Catalog

GOOD CLINICAL PRACTICE (GCP) Series Catalog GOOD CLINICAL PRACTICE (GCP) Series Catalog CITI Program s GCP series consists of three basic courses and three refresher courses. The basic courses include: GCP for Clinical Trials with Investigational

More information